Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*

被引：0
|
作者：
Bonella, Autoren F. [1 ]
Moua, T. [2 ]
Okamoto, M. [3 ]
Tomassetti, S. [4 ]
Valenzuela, C. [5 ]
Wuyts, W. [6 ]
Miede, C. [7 ]
Lievens, D. [8 ]
Bendstrup, E. [9 ]
机构：
[1] Univ Duisburg Essen, Zentrum Interstitielle & Seltene Lungenkrankheite, Klin Pneumol,Univ Med Essen, Ruhrlandklin,Univ Klinikum,Westdeutsch Lungenzent, Duisburg, Germany
[2] Mayo Clin Rochester, Div Pulm & Crit Care Med, Rochester, MN USA
[3] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan
[4] Careggi Univ Hosp, Dept Expt & Clin Med, Florence, Italy
[5] Univ Autonoma Madrid, Hosp Univ Princesa, Madrid, Spain
[6] Univ Hosp Leuven, Dept Pulm Med, Unit Interstitial Lung Dis, Leuven, Belgium
[7] Mainanalyt GmbH, Sulzbach, Germany
[8] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[9] Aarhus Univ Hosp, Dept Resp Dis & Allergy, Ctr Rare Lung Dis, Aarhus, Denmark
来源：
PNEUMOLOGIE | 2023年 / 77卷
关键词：
D O I：
10.1055/s-0043-1761002
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Po 256
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [31] Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
    Matteson, Eric
    Antin-Ozerkis, Danielle
    Bonella, Francesco
    Chaudhuri, Nazia
    Cottin, Vincent
    Mueller, Heiko
    Coeck, Carl
    Rohr, Klaus
    Wuyts, Wim
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 260 - 262
  • [32] Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
    Matteson, Eric
    Distler, Oliver
    Distler, Joerg H. W.
    Kuwana, Masataka
    Pope, Janet
    Seibold, James
    James, Alexandra
    Schlenker-Herceg, Rozsa
    Rohr, Klaus
    Flaherty, Kevin
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [33] HEALTHCARE RESOURCE UTILIZATION AND RELATED COSTS IN PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS)
    Olson, A.
    Hartmann, N.
    Patnaik, P.
    Garry, E.
    Bohn, R.
    Singer, D.
    Baldwin, M.
    Wallace, L.
    VALUE IN HEALTH, 2020, 23 : S353 - S353
  • [34] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Vincent Cottin
    Fernando J. Martinez
    R. Gisli Jenkins
    John A. Belperio
    Hideya Kitamura
    Maria Molina-Molina
    Inga Tschoepe
    Carl Coeck
    Dirk Lievens
    Ulrich Costabel
    Respiratory Research, 23
  • [35] Does HRCT pattern influence the effect of nintedanib in patients with progressive fibrosing interstitial lung diseases?
    Behr, J.
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J. W.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R. G.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    PNEUMOLOGIE, 2021, 75 : S31 - S32
  • [36] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Cottin, Vincent
    Martinez, Fernando J.
    Jenkins, R. Gisli
    Belperio, John A.
    Kitamura, Hideya
    Molina-Molina, Maria
    Tschoepe, Inga
    Coeck, Carl
    Lievens, Dirk
    Costabel, Ulrich
    RESPIRATORY RESEARCH, 2022, 23 (01)
  • [37] Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [38] Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
    Inoue, Yoshikazu
    Wells, Athol U.
    Song, Jin Woo
    Xu, Zuojun
    Kitamura, Hideya
    Suda, Takafumi
    Okamoto, Masaki
    Mueller, Heiko
    Coeck, Carl
    Rohr, Klaus B.
    Kolb, Martin
    Brown, Kevin K.
    RESPIROLOGY, 2023, 28 (05) : 465 - 474
  • [39] Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
    Chaudhuri, Nazia
    Azuma, Arata
    Sroka-Saidi, Kamila
    Erhardt, Elvira
    Ritter, Ivana
    Harari, Sergio
    ADVANCES IN THERAPY, 2024, 41 (12) : 4581 - 4590
  • [40] Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analyses from the INBUILD Trial
    Kolb, M. R.
    Flaherty, K. R.
    Silva, R. S.
    Prasse, A.
    Patel, N. M.
    Vancheri, C.
    Quaresma, M.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345